IP Library Granted Patent US 7,449,456
Granted Patent B2
US 7,449,456 · App. 10/518,043 · Granted Nov 11, 2008

Diaminopyrimidinecarboxamide derivative

Assignee: Astellas Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,449,456
App. No.
10/518,043
Granted
Nov 11, 2008
Kind
B2
Abstract

A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

Claims (70)

1. A compound represented by a formula (I) or salt thereof,

wherein

A 1 : CR 5 or N,

R 5 : —H, -lower alkyl, —O-lower alkyl or -halogen,

A 2 : CR 6 or N,

R 6 : —H or -halogen,

R 3 : —R 0 , -lower alkyl substituted with halogen, -halogen,

—OR 0 , —S-lower alkyl, —CO-lower alkyl, —CO 2 -lower alkyl, -lower alkylene-OH, -hetero ring, —O-hetero ring, —N(R 0 )-hetero ring, -lower alkylene-hetero ring, —O-lower alkylene-hetero ring, —S-lower alkylene-hetero ring, —SO-lower alkylene-hetero ring, —SO 2 -lower alkylene-hetero ring, —N(R 0 )-lower alkylene-hetero ring, -lower alkylene-CO-hetero ring, -lower alkylene-N(R 0 ) 2 , —SO 2 —N(R 0 )-lower alkyl or -lower alkylene-N(R 0 )—CO 2 -lower alkylene-phenyl,

R 0 : the same or different from one another, and each is H or a lower alkyl,

n: 0 or 2,

R 4 : (i) when n=2, —R 0 , -lower alkyl substituted with halogen, —OR 0 , —N(R 0 )—CHO, —N(R 0 )—CO-lower alkyl or —N(R 0 )—SO 2 -lower alkyl,

(ii) when n=0, —H, -lower alkyl substituted with halogen, —OH, —NH—CHO, —CON(R 0 ) 2 , -lower alkylene substituted with halogen-OH, -lower alkylene-NH 2 , -lower alkylene-NHCONH 2 , -lower alkylene-CO 2 H, -lower alkylene-CO 2 -lower alkyl, -lower alkylene-CN, or —CH(lower alkylene-OH) 2 , or a group represented by a formula —X a —R 4a ,

X a : single bond, —O—, —CO—, —S—, —SO 2 —, —N(R 0 )—, —N(R 0 )CO—, —N(R 0 )SO 2 —, -lower alkylene-O—, -lower alkylene-N(R 0 )—, -lower alkylene-N(R 0 )CO—, -lower alkylene-N(R 0 )SO 2 —, -lower alkylene-N(R 0 )CO 2 —, —N(CO—R 0 )—, —N(SO 2 -lower alkyl)-, —CON(R 0 )—, -lower alkylene-O—CO—, -lower alkenylene-CO—, -lower alkenylene-CON(R 0 )—, -lower alkenylene-CO 2 —, —O—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —N(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CO—(CH 2 ) k -cycloalkylene -(CH 2 ) m —, —CON(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m — or —N(R 0 )CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m -,

k and m, the same or different from each other, and each is 0, 1, 2, 3 or 4,

R 4a : lower alkyl, phenyl, hetero ring, cycloalkyl, lower alkylene-phenyl, lower alkylene-hetero ring, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-hetero ring,

wherein the hetero rings in R 3 and R 4a may be substituted with 1 to 5 of lower alkyl, halogen, —OR 0 , —S-lower alkyl, —S(O)-lower alkyl, —SO 2 -lower alkyl, lower alkylene-OR 0 , —N(R 0 ) 2 , —CO 2 R 0 , —CON(R 0 ) 2 , —CN, —CHO, —SO 2 N(R 0 ) 2 , —N(R 0 )—SO 2 -lower alkyl, —N(R 0 )—CO—N(R 0 ) 2 , —N(R 0 )—CO 2 -lower alkyl, —N(R 0 )—CO 2 -cycloalkyl, —NH—C(═NH)—NH-lower alkyl, —NH—C(═N—CN)—NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH—C(═NN)—NH 2 , —O-phenyl, —CO-phenyl, —N(R 0 )—CO-lower alkyl, —N(R 0 )—CO-lower alkylene —N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkylene-N(R 0 ) 2 , —CO—N(R 0 )-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-CO 2 R 0 , -lower alkylene-N(R 0 ) 2 , -lower alkylene-CO 2 R 0 , -lower alkylene-CO—N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkyl, -lower alkylene-N(R 0 )—CO 2 -lower alkyl, -lower alkylene-N(R 0 )—SO 2 -lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, ═N—O—R 0 or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R 0 ) 2 , and

wherein the lower alkylene in R 3 , R 4 , R 4a and X a may be substituted with 1 to 5 of —OR 0 , —CO 2 R 0 , —CON(R 0 ) 2 , —N(R 0 ) 2 , —N(R 0 )COR 0 or hetero ring, or

R 3 and R 4 may together form *—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—, *—CH 2 —N(R 7 )—CH 2 —, *—N(R 7 )—(CH 2 ) 3 —, *—(CH 2 ) 3 —N(R 7 )—, *—CH 2 —N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—CH 2 —, *—C(O)—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—C(O)—, *—N(R 7 )—CH═CH—, *—CH═CH—N(R 7 )—, *—N═CH—CH═CH—, *—CH═N—CH═CH—, *—CH═CH—N═CH—, *—CH═CH—CH═N—, *—N═CH—CH═N—, *—CH═N—N═CH—, *—N(R 7 )—N═CH—, *—CH═N—N(R 7 )—, *—O—CH 2 —O—, *—O—(CH 2 ) 2 —O—, *—O—(CH 2 ) 3 —O—, *—O—(CH 2 ) 2 —N(R 7 )—, *—(CH 2 ) 2 —C(O)—, *—CH═CH—C(O)—O— or *—N═C(CF 3 )—NH—,

wherein * indicates bonding to the position shown by R 3 ,

R 7 : —H, -lower alkyl or —CO-lower alkyl,

B: cycloalkyl which may have a substituent(s),

Y: single bond, and

R 1 and R 2 : the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

2. A compound represented by a formula (Ia) or a salt thereof,

wherein

A 1 : CR 5 or N,

R 5 : —H, -lower alkyl, —O-lower alkyl or -halogen,

R 3 : —R 0 , -lower alkyl substituted with halogen, -halogen, —OR 0 , —S-lower alkyl, —CO-lower alkyl, —CO 2 -lower alkyl, -lower alkylene-OH, -saturated hetero ring, -X b -heteroaryl, -X b -saturated hetero ring, —X b -heteroaryl, -lower alkylene-N(R 0 ) 2 , —SO 2 —N(R 0 )-lower alkyl or -lower alkylene-N(R 0 )—CO 2 -lower alkylene-phenyl,

X b : -lower alkylene-, —O-lower alkylene-, —S-lower alkylene-, —SO-lower alkylene-, —SO 2 -lower alkylene-, —N(R 0 )-lower alkylene- or -lower alkylene-CO—,

R 0 : the same or different from one another, and each represents H or a lower alkyl,

R 4 : —X a -saturated hetero ring, -lower alkylene-saturated hetero ring or -lower alkenylene-saturated hetero ring,

X a : single bond, —O—, —CO—, —S—, —SO 2 —, —N(R 0 )—, —N(R 0 )CO—, —N(R 0 )SO 2 —, -lower alkylene -O—, -lower alkylene-N(R 0 )—, -lower alkylene-N(R 0 )CO— or -lower alkylene-N(R 0 )SO 2 —, -lower alkylene-N(R 0 )CO 2 —, —N(CO—R 0 )—, —N(SO 2 -lower alkyl)-, —CON(R 0 )—, -lower alkylene-O—CO—, -lower alkenylene-CO—, -lower alkenylene-CON(R 0 )—, -lower alkenylene-CO 2 —, —O—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —N(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CO—(CH 2 ) k -cycloalkylene (CH 2 ) m —, —CON(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m — or —N(R 0 )CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —,

k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4,

wherein the saturated hetero rings in R 3 and R 4a may be substituted with 1 to 5 of lower alkyl, halogen, —OR 0 , —S-lower alkyl, —S(O)-lower alkyl, —SO 2 -lower alkyl, lower alkylene-OR 0 , —N(R 0 ) 2 , —CO 2 R 0 , —CON(R 0 ) 2 , —CN, —CHO,—SO 2 N(R 0 ) 2 , —N(R 0 )—SO 2 -lower alkyl, —N(R 0 )—CO—N(R 0 ) 2 , —N(R 0 )—CO 2 -lower alkyl, —N(R 0 )—CO 2 -cycloalkyl, —NH—C(═NH)—NH-lower alkyl, —NH—C(═N—CN)—NH-lower alkyl, saturated hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), heteroaryl, -lower alkylene NH—C(═NN)—NH 2 , —O-phenyl, —CO-phenyl, —N(R 0 )—CO-lower alkyl, —N(R 0 )—CO-lower alkylene -N(R 0 ) 2 , -lower alkylene (R 0 )—CO-lower alkylene-N(R 0 ) 2 , —CO—N(R 0 )-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-CO 2 R 0 , -lower alkylene-N(R 0 ) 2 , -lower alkylene-CO 2 R 0 , -lower alkylene-CO—N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkyl, -lower alkylene-N(R 0 )—CO 2 -lower alkyl, -lower alkylene-N(R 0 )—SO 2 -lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, ═N—O—R 0 or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R 0 ) 2 , and

wherein the lower alkylene in R 3 , R 4 and X a may be substituted with 1 to 5 of —OR 0 , —CO 2 R 0 , —CON(R 0 ) 2 , —N(R 0 ) 2 , —N(R 0 )COR 0 or hetero ring, or

R 3 and R 4 may together form *—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—, *—CH 2 —N(R 7 )—CH 2 —, *—N(R 7 )—(CH 2 ) 3 —, *—(CH 2 ) 3 —N(R 7 )—, *—CH 2 —N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—CH 2 —, *—C(O)—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—C(O)—, *—N(R 7 )—CH═CH—, *—CH═CH—N(R 7 )—, *—N═CH—CH═CH—, *—CH═N—CH═CH—, *—CH═CH—N═CH—, *—CH═CH—CH═N—, *—N═CH—CH═N—, *—CH═N—N═CH—, *—N(R 7 )—N═CH—, *—CH═N—N(R 7 )—, *—O—CH 2 —O—, *—O—(CH 2 ) 2 —O—, *—O—(CH 2 ) 3 —O—, *—O—(CH 2 ) 2 —N(R 7 )—, *—(CH 2 ) 2 —C(O)—, *—CH═CH—C(O)—O— or *—N═C(CF 3 )—NH—, wherein * indicates bonding to the position shown by R 3 ,

R 7 : —H, -lower alkyl or —CO-lower alkyl,

B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and

R 1 and R 2 : the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

3. A compound represented by a formula (Ib) or a salt thereof,

wherein

A 1 : CR 5 or N,

R 5 : —H, -lower alkyl, —O-lower alkyl or -halogen,

R 3 : -saturated hetero ring or —X b -saturated hetero ring,

X b : -lower alkylene-, —O—, —N(R 0 )—, —O-lower alkylene-, —S-lower alkylene-, —SO-lower alkylene-, —SO 2 -lower alkylene-, —N(R 0 )-lower alkylene- or -lower alkylene-CO—,

R 0 : the same or different from one another, and each represents H or a lower alkyl,

R 4 : —H, -lower alkyl substituted with halogen, —OH, —NH—CHO, —CON(R 0 ) 2 , -lower alkylene substituted with halogen-OH, -lower alkylene-NH 2 , -lower alkylene-NHCONH 2 , -lower alkylene-CO 2 H, -lower alkylene-CO 2 -lower alkyl, -lower alkylene-CN, —CH(lower alkylene-OH) 2 or -Xa-R 4a ,

X a : single bond, —O—, —CO—, —S—, —SO 2 —, —N(R 0 )—, —N(R 0 )CO—, —N(R 0 )SO 2 —, -lower alkylene -O—, -lower alkylene-N(R 0 )—, -lower alkylene-N(R 0 )CO— or -lower alkylene-N(R 0 )SO 2 —, -lower alkylene-N(R 0 )CO 2 —, —N(CO—R 0 )—, —N(SO 2 -lower alkyl)-, —CON(R 0 )—, -lower alkylene-O—CO—, -lower alkenylene-CO—, -lower alkenylene-CON(R 0 )—, -lower alkenylene-CO 2 —, —O—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —N(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m —, —CO—(CH 2 ) k -cycloalkylene -(CH 2 ) m —, —CON(R 0 )—(CH 2 ) k -cycloalkylene-(CH 2 ) m — or —N(R 0 )CO—(CH 2 ) k -cycloalkylene-(CH 2 ) m —,

k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4,

R 4a : lower alkyl, phenyl, heteroaryl, cycloalkyl, lower alkylene-phenyl, lower alkylene-heteroaryl, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-heteroaryl,

wherein the saturated hetero ring and heteroaryl in R 3 and R 4a may be substituted with 1 to 5 of lower alkyl, halogen, —OR 0 , —S-lower alkyl, —S(O)-lower alkyl, —SO 2 -lower alkyl, lower alkylene-OR 0 , —N(R 0 ) 2 , —CO 2 R 0 , —CON(R 0 ) 2 , —CN, —CHO, —SO 2 N(R 0 ) 2 , —N(R 0 )—SO 2 -lower alkyl, —N(R 0 )—CO—N(R 0 ) 2 , —N(R 0 )—CO 2 -lower alkyl, —N(R 0 )—CO 2 -cycloalkyl, —NH—C(═NH)—NH-lower alkyl, —NH—C(═N—CN)—NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH—C(═NN)—NH 2 , —O-phenyl, —CO-phenyl, —N(R 0 )—CO-lower alkyl, —N(R 0 )—CO-lower alkylene -N(R 0 ) 2 , -lower alkylene-NR)—CO-lower alkylene-N(R 0 ) 2 , —CO—N(R 0 )-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-N(R 0 ) 2 , —CO-lower alkylene-CO 2 R 0 , -lower alkylene-N(R 0 ) 2 , -lower alkylene-CO 2 R 0 , -lower alkylene-CO—N(R 0 ) 2 , -lower alkylene-N(R 0 )—CO-lower alkyl, -lower alkylene-N(R 0 )—CO 2 -lower alkyl, -lower alkylene-N(R 0 )—SO 2 -lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, ═N—O—R 0 or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R 0 ) 2 , or the lower alkylene in R 3 , R 4 , R 4a and X a may be substituted with 1 to 5 of —OR 0 , —CO 2 R 0 , —CON(R 0 ) 2 , —N(R 0 ) 2 , —N(R 0 )COR 0 or hetero ring, or

R 3 and R 4 may together form *—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—, *—CH 2 —N(R 7 )—CH 2 —, *—N(R 7 )—(CH 2 ) 3 —, *—(CH 2 ) 3 —N(R 7 )—, *—CH 2 —N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—CH 2 —, *—C(O)—N(R 7 )—(CH 2 ) 2 —, *—(CH 2 ) 2 —N(R 7 )—C(O)—, *—N(R 7 )—CH═CH—, *—CH═CH—N(R 7 )—, *—N═CH—CH═CH—, *—CH═N—CH═CH—, *—CH═CH—N═CH—, *—CH═CH—CH═N—, *—N═CH—CH═N—, *—CH═N—N═CH—, *—N(R 7 )—N═CH—, *—CH═N—N(R 7 )—, *—O—CH 2 —O—, *—O—(CH 2 ) 2 —O—, *—O—(CH 2 ) 3 —O—, *—O—(CH 2 ) 2 —N(R 7 )—, *—(CH 2 ) 2 —C(O)—, *—CH═CH—C(O)—O— or *—N═C(CF 3 )—NH—, wherein * indicates bonding to the position shown by R 3 ,

R 7 : —H, -lower alkyl or —CO-lower alkyl,

B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and

R 1 and R 2 : the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

4. A compound selected from the group consisting of 4-benzylamino-2-[(4-morpho lin-4-ylphenyl)amino]pyrimidine-5 -carboxamide, 2-[(4-morpholin-4-ylphenyl )amino]-4-[(2,3 ,6-trifluorobenzyl)amino]pyrimidine-5 -carboxamide, 4-[(2,5 -difluorobenzyl) amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5 -carboxamide, 4-[(2,6-difluorobenzyl) amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5 -carboxamide, 4-[(2-methoxybenzyl) amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5 -carboxamide, 4-[(2-fluoro -6-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5 -carboxamide, 2-( {4-[(1 -methylpiperidin-3 -yl)oxy]phenyl}amino)-4-[(2,3 ,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-( 1 -azabicyclo [2.2.2]oct-3-yloxy)phenyl]amino }-4-[(2,3 ,6-trifluorobenzyl) amino]pyrimidine-5 -carboxamide, 2- [(4-methyl-3 ,4-dihydro-2H- 1 ,4-benzoxazin-7-yl)amino]-4- [(2,3,6-trifluorobenzyl)amino]pyrimidine-5 -carboxamide, 2-( {4- [4-(2-amino-2-oxoethyl) piperazin- 1 -yl]phenyl}amino)-4- [(2,3 ,6-trifluorobenzyl)amino]pyrimidine-5 - carboxamide, 2- {[4-(2-morpho lin-4-ylethoxy)phenyl]amino }-4- [(2,3,6-trifluorobenzyl) amino]pyrimidine-5 -carboxamide, 2- {[4-(β-D-glucopyranosyloxy) phenyl]amino }-4-[(2,3 ,6-trifluorobenzyl)amino]pyrimidine-5 -carboxamide, 4-benzylamino-2- {[2-(3 -chloro-4-hydroxyphenyl)ethyl]amino }pyrimidine-5 -carboxamide, 4 - benzylamino-2- {[2-(3 , 5 -dichioro -4-hydroxyphenyl)ethyl]amino }pyrimidine-5 -carboxamide, 2- [(4-morpholin-4-ylphenyl)amino]-4- [(2-thienylmethyl)amino]pyrimidine-5 -carboxamide, 4- {[(3-chloro-2-thienyl)methyl]amino }-2- [(4-morpholin-4-ylphenyl)amino]pyrimidine-5 -carboxamide and 2- {[3 -(2-morpholin-4-ylethyl)phenyl]amino }-4- [(2,3 ,6-trifluorobenzyl)amino]pyrimidine-5 -carboxamide or salts thereof

5. The compound of claim 1 wherein B is a cycloalkyl.

6. The compound of claim 5 wherein B is cyclopropyl or cyclobutyl which may have substituent(s).

7. The compound of claim 6 wherein B is cyclopropyl or cyclobutyl.

8. The compound of claim 5 wherein R 1 and R 2 are both H.

9. The compound of claim 5 wherein A 1 is CR 5 and A 2 is CR 6 , and wherein R 5 and R 6 are both H.

10. The compound of claim 5 wherein R 3 is —R 0 ,-halogen or -hetero ring, and wherein R 0 is H or lower alkyl.

11. The compound of claim 10 wherein R 3 is -hetero ring substituted with 1 to 5 of lower alkyl, —OH, —SO 2 -lower alkyl, lower alkylene-OR 0 , —CO 2 R 0 ,—CON(R 0 ) 2 or —N(R 0 )—CO-lower alkyl.

12. The compound of claim 5 wherein n is 0 .

13. The compound of claim 12 wherein R 4 is —X a —R 4a , and wherein X a is a single bond, —CO—, —SO 2 —, —N(R 0 )CO—or —N(R 0 )SO 2 —, and R 4a is lower alkyl, phenyl, hetero ring, cycloalkyl or lower alkylene-OH.

14. The compound of claim 13 wherein R 4a is hetero ring substituted with 1 to 5 of lower alkyl, —OH, —SO 2 -lower alkyl, lower alkylene-OR 0 ,—CO 2 R 0 ,—CON(R 0 ) 2 or —N(R 0 )—CO-lower alkyl.

15. The compound of claim 5 wherein R 3 and R 4 taken together form *—N(R 7 )—CH═CH—, *—N(R 7 )—N═CH—or *—CH═N—N(R 7 )—, wherein * indicates bonding to the position shown by R 3 .

16. A composition comprises a compound of any one of claims 1 , 2 or 3 , or a salt thereof and pharmaceutically acceptable carrier.

17. A method for treating asthma comprising administering an effective amount of a compound or a salt thereof, according to any one of claims 1 , 2 or 3 , to the subject, wherein the subject is a mammal.

18. A method for treating a chronic obstructive pulmonary disease (COPD) comprising administering an effective amount of a compound or a salt thereof, according to any one of claim 1 , 2 or 3 , to the subject wherein the subject is a mammal.

Assignments (2)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2004
From: NAGASHIMA, SHINYA; NAGATA, HIROSHI; IWATA, MASASHIRO; YOKOTA, MASAKI; MORITOMO, HIROYUKI; NAKAI, EIICHI; KUROMITSU, SADAO; OHGA, KEIKO; TAKEUCHI, MAKOTO
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 016805/0921 →
Priority Claims (1)
JP 2002-190959 · Jun 28, 2002 · national
Continuity (1)
Related Publication 20050272753A1 · Dec 8, 2005